Goldline Pharmaceutical IPO Details
Goldline Pharmaceutical IPO Summary
Goldline Pharmaceutical IPO opens for subscription on 12 May 2026 and closes on 14 May 2026.The IPO will be listed on BSE with the tentative listing date set for 19 May 2026.
Goldline Pharmaceutical IPO price band has been fixed at ₹41 – ₹43 per share. The face value is ₹10 per share with a lot size of 3000.
Goldline Pharmaceutical IPO total issue size comprises 27,00,000 shares (aggregating up to ₹11.61 Cr). This includes a fresh issue of 27,00,000 shares (aggregating up to ₹11.61 Cr). Pre-issue shareholding stands at 69,00,000, which will increase to 96,00,000 post-issue.
Goldline Pharmaceutical IPO carries a ₹15 (34.88%) GMP, reflecting investor sentiment.
Goldline Pharmaceutical IPO Lot Size :Individual Minimum is 2 lots (6,000 shares) amounting to ₹258,000. Individual Maximum is 2 lots (6,000 shares) amounting to ₹258,000. SHNI Minimum is 3 lots (9,000 shares) amounting to ₹387,000. SHNI Maximum is 7 lots (21,000 shares) amounting to ₹903,000. BHNI Minimum is 8 lots (24,000 shares) amounting to ₹1,032,000.
Goldline Pharmaceutical IPO Details
Goldline Pharmaceutical IPO Subscription
Goldline Pharmaceutical IPO Application Wise Breakup
Goldline Pharmaceutical IPO Dates
- 12 May 2026Opening dateOpen
- 14 May 2026Closing dateClose
- 15 May 2026Allotment Date Allotment
- 18 May 2026Initiation of RefundsRefund
- 18 May 2026Credit of SharesCredit
- 19 May 2026Listing dateListing
Goldline Pharmaceutical IPO Lot Size
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Individual Minimum | 2 | 6000 | ₹258,000 |
| Individual Maximum | 2 | 6000 | ₹258,000 |
| SHNI Minimum | 3 | 9000 | ₹387,000 |
| SHNI Maximum | 7 | 21000 | ₹903,000 |
| BHNI Minimum | 8 | 24000 | ₹1,032,000 |
Goldline Pharmaceutical IPO Reservation
Promoter Holding
Documents
Goldline Pharmaceutical IPO Valuations
Goldline Pharmaceutical Financial Information
| Period Ended | 31 Dec 2025 | 31 Mar 2025 | 31 Mar 2024 | 31 Mar 2023 |
|---|---|---|---|---|
| Assets | 27.40 | 26.28 | 22.93 | 19.39 |
| Total Income | 21.41 | 28.06 | 23.57 | 19.85 |
| Profit After Tax | 2.22 | 2.83 | 1.81 | 0.26 |
| EBITDA | 4.16 | 5.83 | 4.30 | 2.19 |
| NET Worth | 12.36 | 10.35 | 7.86 | 5.89 |
| Reserves and Surplus | 3.65 | 1.65 | 3.76 | 2.08 |
| Total Borrowing | 9.47 | 11.03 | 11.13 | 10.83 |
| Amount in ₹ Crore | ||||
About Goldline Pharmaceutical IPO
Goldline Pharmaceuticals is engaged in the business of marketing pharmaceutical products under the brand name “Goldline.” Its product range is divided into five segments:
- Goldline Pharma: This category includes 42 products to cater to specialties like Physicians, Orthopedics, ENT, Chest Physicians, General and Specialty Surgery, Gastroenterology, Neurology, and Urology.
- Goldline Cardinal: This category offers 54 products tailored for the Specialty division, serving medical fields such as Physicians, Diabetologists, Endocrinologists, Cardiologists, and General Physicians.
- Goldline Aayushman: This category comprises 18 products designed for the Specialty division, catering to medical fields such as Pediatricians, Child Specialists, Neonatologists, and General Practitioners.
- Goldline InLife: This category includes 22 products tailored for the Specialty division, serving Intensivists, Critical Care Consultants, Super Specialty Surgeons, and Physicians.
- Goldline Wellness: This category includes 10 products tailored Supportive care plays a crucial role in cancer therapy.
The company do not manufacture products, it partner with third-party manufacturers who produce the medicines based on its market research and product specifications, ensuring quality and compliance with regulations.
All products are marketed and sold under the Goldline brand through our network of distributors, who supply to retailers and wholesalers. The company currently works with 15 manufacturers and 7 distributors, and it also support hospitals and healthcare providers with procurement and material supply.
The company sells products across the states of Maharashtra, Madhya Pradesh, Odisha, Jharkhand, Tamil Nadu, Rajasthan, and Bihar.
Strength Of Goldline Pharmaceutical IPO
- Experienced promoters and management team with industry knowledge and a track record.
- Asset-light business model and competitive products.
- Scalable Business Model.
- Wide and diverse range of product offerings.
- Strong Supplier and Vendor Relationships.
- Established Distribution Network.
Risk Of Goldline Pharmaceutical IPO
- Its rely entirely on third-party contract manufacturers for the manufacturing of the company pharmaceutical products, and any failure or inability of such manufacturers to meet quality, regulatory, delivery or capacity requirements could adversely affect its business, results of operations and financial condition.
- The Company has experienced delays in filing e-forms with the Registrar of Companies (RoC) in the past, resulting in the payment of late fees. Further, there have also been instances of erroneous filings made by the Company, in the past. While no regulatory actions or penalties has been imposed to date except below mentioned, there is no assurance that such actions will not be levied in the future. The Company cannot guarantee that similar delays will not occur in the future, and if regulatory authorities impose penalties or take punitive actions against the Company or its directors/officers, it could negatively affect the Company's business and financial condition.
- The company commercial success is largely dependent upon its ability to analyses the market of new pharmaceutical products, failure of which may has an adverse impact on its revenue and profitability.
- There has been instances of delays in payment of statutory dues, i.e. GST by the Company. In case of any delay in payment of statutory due in future by the Company, the Regulatory Authorities may impose monetary penalties on it or take certain punitive actions against the Company in relation to the same which may has adverse impact on its business, financial condition and results of operations.
- Its depend on the company distributors for a significant portion of its revenue, and any decrease in revenues or sales from any one of the company key intermediaries may adversely affect its business and results of operations. the Company has a distribution network of 8 distributors and is dependent on these distributors for a significant portion of its revenue. If the company unable to maintain its relationship with such customers or if there is a reduction in their demand for the company products, its business, results of operations and financial condition will be materially and adversely affected.
- There are outstanding mitigations involving the Company, Promoters, Directors, Key Managerial Personnel, Senior Management and Group Companies, if determined adversely, may adversely affect its business and financial condition.
- The company Promoter Group entities Numerius Healthcare Private Limited, Nucleage Lifescience Private Limited and Nucleage Pharma Solutions Private Limited has conflicts of interest as they are engaged in similar business and may compete with it.
- Its derive a significant portion of the company revenue from certain of its products. If sales volume or price of such products declines in the future, or if the company unable to sell such products for any reason, its business, financial condition, cash flows and results of operations could be adversely affected.
- The company operate in limited geographies for a significant portion of its revenue and also depends on limited number of customers for the company revenue from operations.
- The Company had negative cash flows in the past years, details of which are given below. Sustained negative cash flow could impact its growth and business.
Objectives Goldline Pharmaceutical IPO
1. Prepayment or repayment of all or a portion of certain outstanding borrowings availed by our company
2. General corporate purposes
Company Contact Details
Goldline Pharmaceutical Ltd.
103, F-1, Leela Apartment, Shilpa HSG Society,
Near Saptagiri Nagar, Shanidham,
Narendra Nagar,
Nagpur, Maharashtra, 440015
Phone: +91 712 2786666
Email: info@goldlinepharma.in
Website: http://www.goldlinepharma.in/
Registrar Contact Details
Goldline Pharmaceutical FAQs
The Goldline Pharmaceutical IPO is a SME public issue comprising 2700000 equity shares with a face value of ₹10 each, aggregating to a total issue size of ₹11.61 Cr. The issue price has been fixed at ₹43 per equity share, and the minimum application size is 3000 shares.
The IPO opens for subscription on 12 May 2026, and closes on 14 May 2026.
Bigshare Services Pvt Ltd has been appointed as the registrar to the issue. The equity shares are proposed to be listed on the BSE
As of now, the current GMP stands at ₹15 (34.88%).
Quick Links
Comments
